Jon Rees PhD

1.7K posts

Jon Rees PhD

Jon Rees PhD

@BiotechJon

CEO, MitoRx Therapeutics. Pioneering therapeutics in mitochondrial-driven disease.

UK, Europe Katılım Haziran 2012
1.3K Takip Edilen1.2K Takipçiler
Jon Rees PhD
Jon Rees PhD@BiotechJon·
Very interesting results in Regulus' #ADPKD oligo program (RGLS8429), an indication *larger* than Parkinson's Disease in patient numbers with about 12.5 million patients worldwide making it the most common monogenic disorder. They report halting cyst growth. #biotech #Regulus
English
0
0
0
186
Jon Rees PhD
Jon Rees PhD@BiotechJon·
MitoRx Therapeutics is presenting at #BIOEurope Spring 2025 sharing the latest data demonstrating weight loss with muscle preservation
Jon Rees PhD tweet media
English
0
0
0
62
Jon Rees PhD
Jon Rees PhD@BiotechJon·
Mizuho's upgraded outlook for $ARQT takes the average one-year price target for Arcutis Biotherapeutics to $19.38, driving intraday gains above 7% fintel.io/sfo/us/arqt
English
0
0
0
228
Jon Rees PhD retweetledi
PKD Charity UK
PKD Charity UK@PKDCharity·
📢Passionate about making a difference? We're looking for a dedicated and motivated CEO to lead our national charity supporting PKD patients, carers, and renal clinicians. Join us in our mission to improve lives. Find out more and apply:pkdcharity.org.uk/about-us/vacan…
PKD Charity UK tweet media
English
0
4
6
585
Jon Rees PhD
Jon Rees PhD@BiotechJon·
I was deeply saddened about the passing of Tess Harris, PKD Charity UK CEO. PKD is one of the most common genetic diseases affecting up to 70,000 people in UK, 600,000 in the US and 12 million worldwide, but remains grossly underserved by our industry. Let's change that.
PKD Charity UK@PKDCharity

💜With profound sorrow, we announce the passing of our beloved CEO, Tess Harris, peacefully on March 1, 2024. A tireless advocate for PKD, her visionary leadership and dedication will forever inspire us.💜 Full statement: bit.ly/TessPKD

English
0
0
2
140
Jon Rees PhD retweetledi
MitoRx Therapeutics
MitoRx Therapeutics@MitoRxTheraLtd·
@BiotechJon will share insights at #BIOEuropeSpring into our first-in-class mitochondriotropic therapeutics, now validated preclinically in mammalia. These restore sulfide-signalling, which can arrest progression in degenerative conditions. 🤝 Book a mtg: lnkd.in/e2EQTn8j
MitoRx Therapeutics tweet media
English
0
1
1
69
Jon Rees PhD
Jon Rees PhD@BiotechJon·
Looking forward to sharing positive preclinical results from MitoRx's programs modulating mitochondrial dysfunction to arrest decline in degenerative diseases at #JPM24 next week...
MitoRx Therapeutics@MitoRxTheraLtd

@Biotechjon is at #BiotechShowcase2024 on Jan 8-9, presenting our groundbreaking therapeutic pipeline targeting mitochondria dysfunction in rare diseases like #Duchenne & #Huntingtons. Hear about our promising preclinical results and recent financing news! tinyurl.com/27ry4v89

English
0
0
2
417
Jon Rees PhD
Jon Rees PhD@BiotechJon·
Preprint alert: Vignane shows oxidation of cysteine residues promotes aberrant LLPS and aggregation (seen in ND) and cysteine persulfidation prevents this. Protective persulfidation is impaired in neurodegeneration, MitoRx restores this. 1 minute summary: sciencecast.org/casts/avlou2k9…
English
0
1
1
133
Jon Rees PhD retweetledi
Glyn Edwards
Glyn Edwards@edwards_glyn·
Really interesting paper validating @MitoRxTheraLtd technology. Mitochondrial sulfide promotes life span and health span through distinct mechanisms in developing versus adult treated Caenorhabditis elegans | PNAS pnas.org/doi/abs/10.107…
English
0
2
2
215
Jon Rees PhD
Jon Rees PhD@BiotechJon·
Over 60% of FDA-approvals of new drugs from the top 20 pharma originate externally (including 6% from collaboration). And only 3% originate in Universities. Read that last bit again. Tell everyone you know this: biotech is the crucible for innovation.
Nature Reviews Drug Discovery@NatRevDrugDisc

Investigating the origins of recent pharmaceutical innovation bit.ly/3D22C9q An analysis of new drugs from the top 20 biopharma companies indicates that their business model in recent years has largely been built on external innovation, as only 28% originated internally

English
0
0
0
125
Jon Rees PhD retweetledi
HM Treasury
HM Treasury@hmtreasury·
Silicon Valley Bank UK has today been sold to @HSBC. This transaction has been facilitated by the @bankofengland in consultation with HM Treasury. No taxpayer money is involved and customer deposits have been protected. Find out more ⬇️ gov.uk/government/new…
English
127
363
776
625.3K

Keşfet

@LongevityTech @oligogirl @HansbroResearch @CarolineGuiner @MilosFi37777561 @MitoRxTheraLtd @HSBC @bankofengland